Compare CALM & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALM | VERA |
|---|---|---|
| Founded | 1957 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.0B |
| IPO Year | 1996 | 2021 |
| Metric | CALM | VERA |
|---|---|---|
| Price | $86.84 | $32.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $92.00 | $81.30 |
| AVG Volume (30 Days) | 994.7K | ★ 2.1M |
| Earning Date | 04-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 11.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.63 | N/A |
| Revenue | ★ $2,911,632,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $472.48 |
| P/E Ratio | $14.10 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $71.92 | $19.07 |
| 52 Week High | $117.45 | $56.05 |
| Indicator | CALM | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 70.24 | 29.92 |
| Support Level | $80.78 | $30.59 |
| Resistance Level | $95.57 | $42.77 |
| Average True Range (ATR) | 3.62 | 2.03 |
| MACD | 0.45 | -1.03 |
| Stochastic Oscillator | 88.06 | 4.21 |
Cal-Maine Foods Inc produces and sells shell eggs. Its main market is the United States. The company's product portfolio contains nutritionally enhanced, cage-free, organic, and brown eggs. Cal-Maine Foods markets the shell eggs to a diverse group of customers, including grocery-store chains, club stores, and food service distributors. The company's brands are Egg-Land's, Land O' Lakes, Farmhouse, and 4-Grain. The Company has one reportable operating segment, which is the production, grading, packaging, marketing and distribution of shell eggs.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.